Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | F13A1 | P00488 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | TGM1 | P22735 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058628 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 | |
| SCHEMBL16765291 | 0.93 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 | |
| SCHEMBL16765293 | 0.93 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 | |
| SCHEMBL16764765 | 0.93 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 | |
| SCHEMBL12563578 | 0.90 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 | |
| SCHEMBL31288381 | 0.90 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 | |
| Hydrochloric Acid SCHEMBL1993108 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 | |
| Hydrochloric Acid SCHEMBL31288372 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 | |
| SCHEMBL1795685 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 | |
| SCHEMBL3335937 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780342-B1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-06-01 | — | — | EP | disclosed |
| US-9181277-B2 | Aminoquinazoline derivatives and their salts and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-11-10 | — | — | US | disclosed |
| EP-2780342-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | Sunshine Lake Pharma Co., Ltd. (CN) | 2014-09-24 | — | — | EP | disclosed |
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-08-14 | — | — | US | disclosed |
| WO-2013071697-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | ABL1, PRKDC, JAK2 | SMN1; SMN2 3702/4885NPC1 2725/4885RAB9A 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.